All In Biotech

Drug Trial Radar · NCT06655896

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis

A Phase II, Multi-part, Randomized, Open-label, Assessor-blinded, Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel Versus Rituximab Treatment in Participants With Severe Refractory Diffuse Cutaneous Systemic Sclerosis

Last checked: Nov 20, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

96

Planned (sponsor's estimate)

Start

Oct 29, 2024

Primary completion

Nov 30, 2028

Study completion Aug 30, 2032

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Oct 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy, safety and tolerability of rapcabtagene autoleucel (administered once following lymphodepletion) in participants with severe refractory diffuse cutaneous systemic sclerosis relative to rituximab.

Conditions

  • Scleroderma, Diffuse

Interventions

  • rapcabtagene autoleucelBiological

    single infusion of rapcabtagene autoleucel after lymphodepleting therapy with fludarabine (adjusted based on renal impairment) and cyclophosphamide daily for 3 days.

  • rituximabBiological

    rituximab intravenous infusion (i.v.) as per protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Achievement of a treatment response as per the Revised Composite Response Index in Systemic Sclerosis 50 (rCRISS50) definition at Week 52.Time frame: Week 52

Locations

93 sites in 22 countries. Site status is shown where the registry gives one.

  • UCLA

    Los Angeles, California

  • UCSF

    San Francisco, California

  • Sutter Health Network

    San Pablo, California

  • FL Medical Clinic Orlando Health

    Zephyrhills, Florida

  • Northwestern University

    Chicago, Illinois

  • University Of Iowa

    Iowa City, Iowa

  • Boston Medical Center

    Boston, Massachusetts

  • Michigan Med University of Michigan

    Ann Arbor, Michigan

  • University of Minnesota

    Minneapolis, Minnesota

  • James Cancer Hospital

    Columbus, Ohio

  • Oregon Health Sciences University

    Portland, Oregon

  • Avera Cancer

    Sioux Falls, South Dakota

  • LDS Hospital

    Salt Lake City, Utah

  • Novartis Investigative Site

    CABA, Argentina

  • Novartis Investigative Site

    Córdoba, Córdoba Province, Argentina

  • Novartis Investigative Site

    Camperdown, New South Wales, Australia

  • Novartis Investigative Site

    Darlinghurst, New South Wales, Australia

  • Novartis Investigative Site

    Graz, Austria

  • Novartis Investigative Site

    Vienna, Austria

  • Novartis Investigative Site

    Vienna, Austria

  • Novartis Investigative Site

    Ghent, Belgium

  • Novartis Investigative Site

    Salvador, Estado de Bahia, Brazil

  • Novartis Investigative Site

    Curitiba, Paraná, Brazil

  • Novartis Investigative Site

    Barretos, São Paulo, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil

  • Novartis Investigative Site

    Olomouc, Czechia

  • Novartis Investigative Site

    Prague, Czechia

  • Novartis Investigative Site

    Aarhus N, Denmark

  • Novartis Investigative Site

    Bordeaux, France

  • Novartis Investigative Site

    Dijon, France

  • Novartis Investigative Site

    Lille, France

  • Novartis Investigative Site

    Lyon, France

  • Novartis Investigative Site

    Montpellier, France

  • Novartis Investigative Site

    Paris, France

  • Novartis Investigative Site

    Rennes, France

  • Novartis Investigative Site

    Strasbourg, France

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Lübeck, Germany

  • Novartis Investigative Site

    Mainz, Germany

Showing 40 of 93 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.